CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 804 enrolled
Drug / intervention
Aclidinium bromide +1 moredrug
Likely dose
Aclidinium bromide 200 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00358436
NCT00358436Phase 3Completed
CompareCT.gov

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

AstraZeneca·interventional·Posted Jul 31, 2006·Updated Jan 4, 2017

In Brief

A Phase 3 clinical trial evaluating Aclidinium bromide and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 804 participants across 120 sites in 7 countries.

Detailed Summary

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesArgentina, Australia, Canada, Mexico, New Zealand, South Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 31, 2006
Enrollment StartAug 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.9 years ago

Interventions

Aclidinium bromidedrug

Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks

Placebodrug

Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks